Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

Exclusion Criteria

• •Patients will be excluded in the case of:
• •* Ascites due to non-malignant cause
• •* Concurrent treatment with systemic chemotherapy that has a realistic chance of controlling the ascites
• •* Concurrent treatment with intraperitoneal Bevacizumab
• •* life expectancy of less than 2 weeks
• •* A history of bowel perforation or fistula
• •* Symptoms or signs suggestive of bacterial peritonitis
• •* Child's C cirrhosis
• •* Uncontrolled hypertension
• •* Surgery within 28 days of catheter treatment
• •* Evidence of coagulopathy
• •* Symptoms suggestive of bowel obstruction
• •* Major surgery, open biopsy or significant traumatic injury within seven (7) days of first study drug--including neurosurgery.
• •* Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.
• •* Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements
• •* Patients who are pregnant or lactating (females of childbearing potential must have a negative pregnancy test prior to participation)
• •* Patients with pre-existing 3 + or greater urine dipstick reading proteinuria